Q3 2025 Bruker Corp Earnings Call Transcript
Key Points
- Bruker Corp (BRKR) reported a better-than-expected Q3 2025 performance, with a meaningful sequential improvement from Q2.
- The company experienced mid-single-digit percentage organic bookings growth, particularly in the academic government market segment and biopharma and applied market orders.
- Innovative solutions in spatial biology, proteomics, and multiomics are being well-received, enhancing leadership in drug discovery and disease biology research.
- Organic scientific instrument orders in China increased by double-digit percentage year-over-year, indicating potential stimulus funding beginning to be dispersed.
- Bruker Corp (BRKR) is on track with cost savings initiatives, aiming for significant margin expansion and double-digit EPS growth in 2026.
- Q3 2025 revenues and earnings were down year-over-year due to weaker demand for academic and research instruments in the first half of 2025.
- The company reported a 0.5% decrease in Q3 2025 revenues, with a 4.5% organic revenue decline.
- Non-GAAP operating margin decreased by 260 basis points year-over-year, impacted by lower revenue absorption, additional tariff costs, and currency headwinds.
- Bruker Corp (BRKR) reduced its organic revenue growth expectations for Q4 2025 and the full year due to late timing of Q3 orders and customer site delays.
- The company reported a non-GAAP EPS of $0.45, down 25% from the previous year, although it showed sequential improvement.
Good day, and welcome to the Bruker Corporation third quarter 2025 earnings conference call. (Operator Instructions). Please note this event is being recorded.
I would now like to turn the conference over to Joe Kostka, Director of Bruker Investor Relations. Please go ahead.
Good morning. I would like to welcome everyone to Bruker Corporation's third quarter 2025 earnings conference call. My name is Joe Kostka, and I am the Director of Bruker Investor Relations. Joining me on today's call are our President and CEO, Frank Laukien; and our EVP and CFO, Gerald Herman.
In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events & Presentations section of Bruker's Investor Relations website.
During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
